PROCEPT BioRobotics EBITDA Margin 2021-2024 | PRCT
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for PROCEPT BioRobotics (PRCT) over the last 10 years. The current EBITDA margin for PROCEPT BioRobotics as of December 31, 2024 is .
| PROCEPT BioRobotics EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2024-12-31 | $0.22B | $-0.09B | -40.63% |
| 2024-09-30 | $0.20B | $-0.10B | -50.50% |
| 2024-06-30 | $0.18B | $-0.11B | -59.32% |
| 2024-03-31 | $0.16B | $-0.10B | -66.24% |
| 2023-12-31 | $0.14B | $-0.11B | -77.94% |
| 2023-09-30 | $0.12B | $-0.10B | -87.93% |
| 2023-06-30 | $0.10B | $-0.10B | -97.03% |
| 2023-03-31 | $0.09B | $-0.09B | -105.88% |
| 2022-12-31 | $0.08B | $-0.08B | -102.67% |
| 2022-09-30 | $0.06B | $-0.07B | -113.11% |
| 2022-06-30 | $0.05B | $-0.06B | -120.00% |
| 2022-03-31 | $0.04B | $-0.06B | -134.15% |
| 2021-12-31 | $0.03B | $-0.05B | -147.06% |
| 2021-06-30 | $0.02B | $-0.03B | -194.12% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $3.077B | $0.225B |
| PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. It focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia. PROCEPT BioRobotics Corporation is based in REDWOOD CITY, Calif. | |||